G
GeneYX
Cloud-based environment that promotes an end to end solution for secured genetic data resource with efficient processing; hence, providing stakeholders with high grade global genetic and medical data
About GeneYX
Geneyx operates in the genetic data analysis and clinical genome research market, serving hospitals, labs, and clinicians globally. The company offers a platform for Next-Generation Sequencing (NGS) data analysis and interpretation, specifically for Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and Gene Panels. Geneyx's platform reduces the time associated with analysis, interpretation, and reporting by 95% through a streamlined, automated workflow. This automation decreases overhead costs and requires less hands-on time, making the process more efficient and cost-effective. The platform also increases diagnostic yield and empowers clinicians with rapid clinical decision support, thereby accelerating the diagnostic process from raw genetic data to clinical reports. Geneyx utilizes the largest unified global knowledge base for interrogating genetic-based diseases and disorders, ensuring high accuracy and up-to-date information. The business model revolves around providing a subscription-based service to medical institutions, generating revenue through recurring fees. The company also focuses on reducing liability for clinical providers by offering auditable, evidence-based reports. Keywords: Genetic Data Analysis, Clinical Genome Research, NGS, WGS, WES, Gene Panels, Automation, Diagnostic Yield, Machine Learning, Bioinformatics.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Ramat Hasharon, Israel
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 68.5/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Tech for Hospitals and Clinics, Clinical Decision Support, Hard Tech, slush24
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Sep 2020
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning GeneYX.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Nov 2021 | $10M | $40M | Accenture · Capri Ventures | — |
| SEED✓Equity / VC | Aug 2020 | $500K | $10M | Magna Capital Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for GeneYX is 42K monthly website visits, up 50% over the last three months. GeneYX's team declined 6.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
- NVNextLeap Ventures
- DGDive digital GMBH
Magna Capital Partners
Accenture
Capri Ventures
Other known investors4 additional known investors
Google for Startups Accelerator
Alex Pinchev
Global Incubator Network
Sarona Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GeneYX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GeneYX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








